Presented at ESMO, the compound shows activity; however, the trial design is problematic.
I would be curious as to how you, or Dr. Prasad, would design a study with this drug to answer the questions you think need to be answered.
Here is my answer : https://www.drugdevletter.com/p/how-to-design-a-trial-to-test-the
This is getting so common. It seems half of oncology drugs are really of questionable benefit. I think I saw a research paper on that somewhere
I would be curious as to how you, or Dr. Prasad, would design a study with this drug to answer the questions you think need to be answered.
Here is my answer : https://www.drugdevletter.com/p/how-to-design-a-trial-to-test-the
This is getting so common. It seems half of oncology drugs are really of questionable benefit. I think I saw a research paper on that somewhere